Soluble CD40 ligand inhibits the growth of non‑Hodgkin's lymphoma cells through the JNK signaling pathway | Zendy

Zhongxin Feng | Zendy; Jishi Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Soluble CD40 ligand inhibits the growth of non‑Hodgkin's lymphoma cells through the JNK signaling pathway

Author(s) -

Zhongxin Feng,

Jishi Wang

Publication year - 2020

Publication title -

oncology letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.766

H-Index - 54

eISSN - 1792-1082

pISSN - 1792-1074

DOI - 10.3892/ol.2020.12318

Subject(s) - apoptosis , cell cycle , mapk/erk pathway , flow cytometry , p38 mitogen activated protein kinases , oncogene , lymphoma , cancer research , cell growth , signal transduction , cd40 , molecular medicine , cell , raji cell , microbiology and biotechnology , chemistry , biology , immunology , biochemistry , cytotoxic t cell , in vitro

The incidence of non-Hodgkin's lymphoma (NHL) has been increasing annually and has become a serious threat to human health. However, the pathogenesis of NHL remains unclear. The present study aimed to investigate the effect of soluble CD40 ligand (sCD40L) on NHL cells and its underlying mechanism. Cell Counting kit-8 assay and flow cytometry apoptosis experiments were conducted to investigate the effects of sCD40L on cell proliferation and apoptosis. Western blotting was performed to detect the protein expression levels of BAX, Bcl-2, ERK, p-ERK, JNK, p-JNK, p38, p-p38 and c-JUN. The results of the present study demonstrated that exogenous sCD40L significantly inhibited the proliferation and promoted the apoptosis of Raji and CA46 cells. Additionally, exogenous sCD40L promoted the apoptosis of lymphoma cells by activating the JNK signaling pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research